
Samsara BioCapital
Palo Alto biotech investor; joined Cambridge spinout T-Therapeutics' $133m Series B in 2026.
Last refreshed: 14 November 2026 · Appears in 1 active topic
Why are American biotech specialists funding Cambridge T-cell drugs?
Timeline for Samsara BioCapital
Joined T-Therapeutics' Series B
UK Startups and Innovation: T-Therapeutics raises $133m in Series BBackground
Samsara BioCapital joined T-Therapeutics' $133m Series B on 5 November 2026 as a new investor. Advent Life Sciences and the British Business Bank co-led the round, and Eli Lilly, Johnson & Johnson Innovation and M Ventures also joined.
Samsara is a biotech investment firm based in Palo Alto, California, founded by Srinivas Akkaraju. It invests in companies turning new biology into drugs for patients with unmet needs.
The Register shows why Cambridge spinouts look abroad: no single British investor class will fund drug development to clinical proof of concept on its own.
Who is Samsara BioCapital?
Who invested in T-Therapeutics' Series B?
Where is Samsara BioCapital based?
Written with AI from Lowdown's published reporting. Not individually reviewed by an editor. Updated 14 November 2026. Editorial standards.